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Abstract 
Aims 
Xultophy is the first fixed co-formulation pen containing insulin degludec and the 
glucagon-like peptide-1 (GLP-1) analogue liraglutide, authorized for type 2 diabetes 
patients since 2014. The aim was to review the clinical effectiveness of Xultophy across 
two hospitals in Wales.  
Methods 
Retrospective review of patients commenced on Xultophy between April 2016 and 
January 2018 was taken. Data related to glycemic control, weight and medication use 
were collected. 
Results 
Ninety-one patients were initiated on Xultophy, and 60 patients had follow-up for at 
least 6 months with a mean age of 57.3 years (47% male). Xultophy was well-tolerated, 
however, abdominal cramps and nausea limited use in three patients. Baseline HbA1c 
and weight were 84.7mmol/mol and 101.5kg. There were significant HbA1c reductions 
of 9.9mmol/mol (p<0.0001) and 13.4mmol/mol (p<0.008) at 6 and 12 months, and non-
significant changes in weight. Patients with an HbA1c over 84mmol/mol showed the 
greatest HbA1c improvement over 6-months. Those prescribed insulin prior to 
Xultophy had less significant improvements in HbA1c than those previously prescribed 
GLP-1 analogues.  
Conclusions  
There were significant reductions in HbA1c and statistically insignificant weight gain 
over 12 months. Switching from GLP-1 analogues to Xultophy was associated with a 
greater HbA1c reduction compared to switching from insulin. 
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Introduction 
Type 2 diabetes (T2D) is a progressive multi-system disorder, characterized by 
impaired post-prandial insulin secretion, increased peripheral insulin resistance and 
abnormal post-prandial incretin release. At the time of diagnosis, most people with T2D 
have lost between 50-80% of their β-cell function (1). The targeted manipulation of 
several key biological pathways responsible for disease progression is important, and 
is increasingly exploited with our improving understanding of the underlying 
pathophysiology of diabetes and ever-growing number of pharmacological options 
used to treat the disease (1). As a result, patients with T2D are sequentially initiated on 
several oral hypoglycemic agents with the addition of basal insulin when oral agents 
fail to achieve the patient’s glycemic target. The titration of basal insulin is 
recommended for the targeted control of fasting plasma glucose (FPG)  (2), but fails to 
significantly address the postprandial glucose (PPG) excursions which typically 
characterize the earlier stages of deteriorating glycemic control (3). Indeed, over 70% 
of patients with T2D fail to achieve an HbA1c target of 7.0% (53mmol/mol) using basal 
insulin and thus require treatment intensification (4). 
 
Traditionally, patients with T2D who are unable to adequately maintain glycemic 
control using basal insulin would require the addition of prandial insulin or a switch to 
pre-mixed insulin formulations (2). The addition of prandial insulin aims to address the 
worsening PPG levels which are associated with worse cardiovascular outcomes and 
all-cause mortality (5), and are frequently seen as the first sign of progressive β-cell 
failure (3). However, treatment intensification with prandial insulin is associated with 
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greater weight gain, hypoglycaemia and difficulties with treatment adherence such as 
insulin dose calculations, which often impede appropriate insulin intensification. 
As a result, targeting PPG excursions with alternative agents is an attractive 
management option. One class of drugs being increasingly used for this purpose are the 
glucagon-like peptide-1 (GLP-1) analogues, which have been available since the 
introduction of exenatide in 2005 (not in the UK until 2007). Since then several other 
GLP-1 analogues have been approved for use, including dulaglutide (2014), liraglutide 
(2009) and lixisenatide (2013) (6). The use of these medications significantly improves 
glycemic control, with one recent meta-analysis demonstrating an HbA1c improvement 
of 0.9-1.4% (10-15 mmol/mol) over 6 months, with the authors concluding that 50% of 
patients using GLP-1 analogues will achieve HbA1c <7.0% within 6 months (7). Their 
effect on HbA1c are due to their targeting of PPG levels whilst improving weight loss 
and reducing hypoglycemia risk compared with insulin (2). Whilst these trial data are 
very encouraging, real-world data indicate that this benefit may not be as good in 
practice. Hall and colleagues found that T2D patients using a GLP-1 analogue 
improved their HbA1c by just 0.6% over 12 months (8), highlighting the difference 
between trial and real-world data. This is likely a result of the increased treatment 
adherence that is noted by participants in clinical trials compared with patients in the 
‘real-world’. This has been noted previously in studies investigating the benefits of 
GLP-1 analogues in T2D patients to account for about 75% of this difference (9). 
 
The mechanism underlying the improved glycemic control associated with basal insulin 
and GLP-1 analogues are likely to complement each other, targeting both the FPG and 
PPG. As a result, combination therapies of GLP-1 analogues and basal insulin have 
been developed and approved for clinical use. Xultophy is a combination of basal 
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insulin degludec and the GLP-1 analogue liraglutide, introduced by Novo Nordisk, and 
approved for use in 2014 (6). NICE recommend the initiation of GLP-1 analogues in 
T2D patients who have poor glycemic control despite triple therapy, and a body mass 
index greater than 35kg/m2, in a specialist care setting, though there is less specific 
guidance on combination therapies such as Xultophy (10). Meta-analysis of 
randomized-controlled trials evaluating Xultophy found that it is effective, with HbA1c 
reductions of 1.89% (21 mmol/mol) and a non-significant weight loss of about 0.81kg 
(11). However, there are few real-world data published on the efficacy of this 
combination regime. In this paper, we evaluate the real-world efficacy of Xultophy in 
T2D patients across two hospital sites in Swansea. 
 
Methods 
Subjects 
A total of 91 T2D patients were identified from our local electronic database who had 
been commenced on Xultophy between April 2016 and January 2018. These patients 
attended follow-up in secondary care across two hospitals; Morriston and Singleton 
hospitals in Swansea. The original analysis of the data took place in March 2018.  
 
We aimed to review the variables at the follow-up visit after 6 months and 12 months 
of starting Xultophy, however, patients were not commenced on Xultophy at the same 
time so therefore at the time of analysis follow-up data was not available for all subjects. 
Outcomes which were reviewed at follow-up included HbA1c, weight, Body Mass 
Index (BMI), Blood Pressure (BP) and estimated Glomerular Filtration Rate (eGFR). 
Data were also collected on previous glucose-lowering therapies that the patients had 
been using prior to commencing Xultophy, including oral agents and insulin.  
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Statistical Analysis  
Paired t tests were used to compare HbA1c, weight, BMI and BP at follow-up at 6 and 
12 months. The mean and standard deviation were used to describe these variables. A 
Wilcoxon signed ranks test was used for the outcome eGFR which were shown by the 
median and interquartile range.  
 
Results  
Baseline characteristics of patients 
At baseline, the sample had mean age 57.3 ±10.3 years, HbA1c 84.7 ±15.2 mmol/mol 
(9.9 ±1.3%), weight 101.5 ±20.5 kg and BMI of 35.6 ±6.8 kg/m2. Of the 91 patients 
commenced on Xultophy, 60 had follow-up data following the first visit. In this cohort, 
47% of the patients were male. Prior to Xultophy initiation, 24 patients were prescribed 
a GLP-1 analogue, 26 prescribed basal insulin and 16 on both basal insulin and GLP-1 
analogue. Four patients were prescribed a combination of metformin, sulphonylurea 
and insulin, 2 patients were prescribed metformin, sulphonylurea and a sodium-glucose 
co-transporter-2 (SGLT-2) inhibitor, 2 prescribed a combination of metformin, SGLT-
2 inhibitor, insulin and GLP-1 analogue, 1 patient was prescribed metformin, dipeptidyl 
peptidase-4 inhibitor (DPP-IVi) and insulin, and 1 patient was prescribed SGLT-2 
inhibitors, GLP-1 analogue and insulin. Three patients were not prescribed any 
pharmacotherapy prior to commencing Xultophy. The drug therapy used in these 
patients prior to the initiation of Xultophy is summarized in Figure 1. Of the 91 patients 
commenced on treatment with Xultophy, 3 discontinued treatment, 2 due to abdominal 
cramps and 1 due to nausea. 
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Changes in glycemic control observed with therapy 
Significant improvements in glycemic control were observed during follow-up. In the 
60 patients with 6-month follow-up data available, the mean HbA1c improved from 
84.7 ±15.2 mmol/mol (9.9 ±1.3%) at baseline to 74.8 ±16.1 mmol/mol (9.0 ±1.4%)  (-
9.9 mmol/mol (0.9%), P< 0.0001). In the 25 patients with 12-month follow up data, a 
statistically significant improvement in the HbA1c was noted from a baseline 84.5 ±13.2 mmol/mol (9.9 ±1.1%) to 71.1 ±16.7 mmol/mol (8.7 ±1.4%) (-13.4 mmol/mol 
(1.2%), P=0.008). We observed statistically non-significant changes in body weight 
from 101.5 ±20.5 kg at baseline to 102.4 ±20.5 kg at 6 months (P=0.26) and from 95.3 ±19.2 kg to 96.3 ±21.2 kg (P=0.54) in those with 12-month follow-up data. Table 1 and 
Table 2 summarize these data at 6 and 12-months, respectively. 
 
We chose a priori to divide into two groups by the median HbA1c (84 mmol/mol 
(9.8%)) to look at response status by HbA1c at 6 months. There was a greater reduction 
observed in the HbA1c in patients with a baseline HbA1c greater than 84 mmol/mol 
(9.8%) (Pre-treatment v post-treatment: 97.6 ±7.0 v 80.7 ±17.6, P<0.0001) compared 
with patients with an HbA1c less than 84 mmol/mol (9.8%) (Pre-treatment v post-
treatment: 73.3 ±8.3 v 69.5 ±12.9, P=0.07). 
 
Patients prescribed insulin ± oral hypoglycemic agents prior to the initiation of 
Xultophy had a statistically non-significant improvement in the HbA1c of -4.0 
mmol/mol (0.4%) (P=0.39), and a non-significant weight gain of 1.3 kg (P=0.84) over 
6 months. Conversely, patients prescribed a GLP-1 analogue ± oral hypoglycemic 
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agents prior to Xultophy were noted to have a significant improvement in HbA1c of -
13.7 mmol/mol (1.3%) (P=0.01) and a non-significant weight gain of 1.7 kg (P=0.13). 
Patients prescribed both insulin and a GLP-1 analogue ± oral hypoglycemic agents, 
before the initiation of Xultophy were observed to improve their HbA1c by 11.7 
mmol/mol (1.1%) over 6 months (P=0.02) and have a non-significant weight gain of 
1.9 kg (P=0.23). The data related to patients using insulin, GLP-1 analogues or both 
insulin and GLP-1 analogues ± oral hypoglycemic agents are presented in Table 3. 
 
For those patients taking insulin only who were switched to Xultophy, we observed no 
statistically significant change in insulin dose before and after the change to Xultophy, 
calculated from the dose steps of Xultophy. The total daily insulin dose pre- and post-
Xultophy were 39 [interquartile range: 24-75] and 39 [24-46], P=0.25. 
 
Additionally there were some changes in BP and eGFR at 6 and 12 months. There were 
statistically non-significant changes in the systolic BP, diastolic BP and at 6 months 
compared with baseline. At 12 months, further changes in these parameter were noted 
in the systolic BP (132 vs 133, P=0.59), diastolic BP (78 vs 82, P=0.03) and eGFR 
(89.0 vs 90.0, P=0.17) compared with baseline. Table 1 and Table 2 summarize these 
data at 6 and 12-months, respectively. 
 
Discussion 
The management of diabetes has evolved over the last 20 years to include greater focus 
on the management of cardiovascular risk as well as glycemic control. Xultophy is the 
first fixed co-formulation pen containing basal insulin (degludec) and a GLP-1 
analogue (liraglutide), approved for use in patients with T2D since 2014. Few ‘real-
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world’ data are available in respect of Xultophy use, because many centers have only 
recently started to use Xultophy in clinical practice.  
 
In this analysis, patients who were initiated on Xultophy demonstrated a statistically 
significant improvement in the HbA1c after 6 and 12 months of using the combination 
drug. The improvement was most notable in patients whose baseline HbA1c was 
greater than 84 mmol/mol (9.8%). This could be because patients who were initially 
prescribed a more than once a day insulin were struggling to manage their diabetes and 
fully comply with treatment with missed doses, finding it easier to manage with the 
once daily injection used with Xultophy.  
 
A meta-analysis conducted by Orme and colleagues (7) found that GLP-1 analogues 
significantly improved both weight loss and overall glycemic control. One randomized 
trial found a non-inferior significant HbA1c reduction in patients with poorly-
controlled T2D using the combination degludec and liraglutide compared with 
continued uptitration of basal insulin glargine. The study also observed a weight loss 
of 1.4 kg over 6 months in those using combination degludec/liraglutide compared with 
1.8kg weight gain in those using insulin glargine alone (12). Furthermore, one 
systematic review demonstrated that Xultophy use resulted in a significant HbA1c 
reduction of 1.3-1.9% (14-21 mmol/mol) in patients with T2D who were previously 
using oral hypoglycemic agents, GLP-1 analogues or basal insulin (13). 
 
The results presented in this paper demonstrate that Xultophy was a weight-neutral 
combination therapy at 6 or 12 months. This may be because of varied compliance with 
dietary and lifestyle measures which support weight loss. Alternatively, it may be that 
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the weight-gain effect of insulin is overcome with the combination of the GLP-1 
analogue, meaning patients gain the benefit in glycemic control associated with insulin, 
without the associated weight gain. Indeed, a meta-analysis conducted by Cai and 
colleagues (11) did not show any significant overall weight reduction with Xultophy in 
randomized-controlled trials, though it confirmed the significant improvement in 
HbA1c associated with its use. 
 
We also observed that patients who were prescribed insulin ± oral agents at the time of 
Xultophy initiation had a lesser improvement in HbA1c compared to those who are 
either on GLP-1 analogues or both insulin and GLP-1 analogues ± oral agents. This 
may imply that these patients had a longer duration of diabetes and therefore less 
remaining beta-cell function. 
 
In conclusion, Xultophy is an effective drug in the intensification of glycemic control 
in patients with T2D who are inadequately controlled using oral antidiabetic 
medications, GLP-1 analogues and to a lesser extent, basal insulin alone. 
 
Limitations  
Xultophy has only been recently recognized as a new therapy for patients with T2D and 
therefore, limited follow-up was available for these patients. Longer term follow-up 
may demonstrate further changes in HbA1c and/or weight, which would further add to 
these findings. 
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Table 1: Glycaemic and weight changes at six months 
 
Table 1: Changes in HbA1c and body weight from baseline to six months. *Wilcoxon 
signed Ranks test. Median and Interquartile range shown. Mean (SD) presented for 
other data and statistical significance was determined by paired t test. 
 
 
 Table 2: Glycaemic and weight changes at twelve months 
 
Table 2: Changes in HbA1c and body weight from baseline to twelve months. 
*Wilcoxon signed Ranks test. Median and Interquartile range shown. Mean (SD) 
presented for other data and statistical significance was determined by paired t test. 
 
 
 
 
 
 
 
Table 3: The impact of previous injectable therapy on response to Xultophy 
Variable Baseline 6 months P value 
Patients previously using insulin (n=13) 
Variable Baseline (n=60) 6 months (n=60) P value 
HbA1c (mmol/mol) 84.7 (15.2) 74.8 (16.1) <0.0001 
Weight (kg) 101.5 (20.5) 102.4 (20.5) 0.26 
Systolic blood 
pressure (mmHg) 136 (16) 136 (15) 0.87 
Diastolic blood 
pressure (mmHg) 79 (7) 81 (7.3) 0.05 
Estimated GFR* 89.0 [70.3-90.0] 85.0 [73.0-90.0] 0.18 
Variable Baseline (n=60) 6 months (n=60) P value 
HbA1c (mmol/mol) 84.5 (13.2) 71.1 (16.7) 0.008 
Weight (kg) 95.3 (19.2) 96.3 (21.2) 0.54 
Systolic blood 
pressure (mmHg) 132 (15) 133 (15) 0.59 
Diastolic blood 
pressure (mmHg) 78 (6) 82 (6) 0.03 
Estimated GFR* 89.0 [70.3-90.0] 90.0 [72.0-90.0] 0.17 
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HbA1c 89.3 (21.9) 85.3 (18.8) 0.39 
Weight 100.5 (16.6) 101.8 (19.6) 0.84 
Patients previously using GLP-1 analogues (n=11) 
HbA1c 86.0 (10.9) 72.3 (15.9) 0.01 
Weight 111.2 (24.3) 112.9 (24.3) 0.13 
Patients previously using GLP-1 analogues and insulin (n=12) 
HbA1c 79.9(11.6) 68.2 (13.6) 0.02 
Weight 91.4 (20.8) 93.3 (20.5) 0.23 
Table 3: Differences in glycaemic and weight changes in response to the initiation of 
Xultophy over 6 months between patients previously using insulin, GLP-1 analogues 
or both. Data are presented as the mean (SD) and statistical significance was determined 
by paired t test. 
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